How I Treat Series on Acute Lymphoblastic Leukemia

How I Treat Series on Acute Lymphoblastic Leukemia

Author: American Society of Hematology January 29, 2026 Duration: 26:27

In this week's episode, Blood Associate editor Dr. Hervé Dombret interviews authors Drs. Sarah K. Tasian and David T. Teachey on their contributions to the How I Treat Series on acute lymphoblastic leukemia. Dr. Tasian's paper, “How I treat Philadelphia chromosome-like acute lymphoblastic leukemia in children, adolescents, and young adults” discusses the different classes of Ph-like ALL and reviews the recent trials investigating TKIs and immunotherapy specifically for this high-risk patient population. Dr. Teachey's paper, “How I treat ETP-ALL in children”, discusses the best current and emerging therapies that may be used in patients with ETP ALL, including nelarabine and other new agents, immunotherapy, and allogeneic HSCT.


See the full How I Treat series in volume 145 issue 1 of Blood.


Produced by the American Society of Hematology, the Blood Podcast serves as an audio companion to the groundbreaking research found in its namesake journal. Each episode delves into the latest published studies, translating complex findings on blood disorders, cancers, and immune system functions into accessible discussions. You'll hear directly from the researchers and clinicians who are shaping the field, as they break down their methodologies, interpret results, and explore the real-world implications for patient care. This isn't just a summary; it's a critical conversation that examines the how and why behind the science, offering context that the printed page alone cannot provide. Whether you're a practicing hematologist, a trainee in the field, or simply fascinated by the intricate world of human biology, this podcast provides a vital stream of knowledge. It connects the dots between laboratory discovery and clinical practice, all while exploring topics that span from foundational biology to cutting-edge therapeutic advances. Tune in for a thoughtful analysis that makes the latest hematology research comprehensible and immediately relevant to your work or curiosity.
Author: Language: English Episodes: 100

Blood Podcast
Podcast Episodes
Spotlight on Acute Myeloid Leukemia [not-audio_url] [/not-audio_url]

Duration: 21:39
In this Spotlight series episode on Acute Myeloid Leukemia, Blood Editor, Dr. Selina Luger interviews Drs. Laura Michaelis and Alexander Perl on their paper in the series titled “The fit older adult with acute myeloid le…
Busulfan-melphalan conditioning in newly diagnosed, transplant-eligible multiple myeloma; and use of spatial transcriptomics to probe the three-dimensional properties of multiple myeloma bone marrow microenvironments [not-audio_url] [/not-audio_url]

Duration: 13:13
In this week's episode we’ll learn more about a study comparing busulfan-melphalan with melphalan alone as the conditioning protocol for newly diagnosed, transplant-eligible multiple myeloma; then we will discuss data on…
How I Treat Wiskott-Alrich syndrome [not-audio_url] [/not-audio_url]

Duration: 13:16
In this How I Treat podcast episode, Laura Michaelis, MD interviews Sung-Yun Pai, MD about their recently published article in Blood journal "How I treat Wiskott-Alrich syndrome". They highlight recent updates in treatme…
Review Series on Acute Lymphoblastic Leukemia (ALL) [not-audio_url] [/not-audio_url]

Duration: 12:38
In this Review Series episode, Associate Editor Dr. Hervé Dombret speaks with Dr. Mark Litzow about the latest immunotherapy advances for Acute Lymphoblastic Leukemia (ALL). The discussion highlights innovative treatment…
Diffuse large B-cell lymphoma’s long-term effects on immune profiles, plasminogen activation and prevention of venous thromboembolism, and PARP inhibitors in hematological malignancies carrying epigenetic mutations [not-audio_url] [/not-audio_url]

Duration: 18:31
In this week's episode we'll learn about persistent changes in immune profiles in patients who have had diffuse large B-cell lymphoma, or DLBCL, and other cancers; that plasminogen activation and plasmin activity do not…